Hypercortisolism is a state of chronic cortisol excess, commonly manifesting as Cushing syndrome. It can result from endogenous ACTH/cortisol overproduction or exogenous glucocorticoid exposure.
A securities class action alleges Corcept misled investors about the regulatory prospects for relacorilant. The suit cites an FDA Complete Response Letter, a 50.4% stock drop, and an April 21, 2026 lead plaintiff deadline.
Corcept Therapeutics executives and directors were sued over alleged misstatements about a drug candidate’s approval prospects. The suit says insider stock sales totaled $97 million while the stock price was artificially inflated.
The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07156370 |
Salivary Cortisol and Hypercortisolism in Type 2 Diabetes |
RECRUITING | |
| NCT06246357 |
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism |
RECRUITING | PHASE2 |
| NCT05368090 |
Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism |
RECRUITING | NA |
